Epigral Ltd
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.
- Market Cap ₹ 8,136 Cr.
- Current Price ₹ 1,886
- High / Low ₹ 2,408 / 1,107
- Stock P/E 22.8
- Book Value ₹ 441
- Dividend Yield 0.27 %
- ROCE 25.2 %
- ROE 22.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE SmallCap BSE Allcap BSE Commodities Nifty Microcap 250 Nifty Total Market
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
829 | 1,551 | 2,188 | 1,929 | 2,550 | |
567 | 1,041 | 1,499 | 1,448 | 1,839 | |
Operating Profit | 261 | 509 | 689 | 481 | 711 |
OPM % | 32% | 33% | 31% | 25% | 28% |
2 | 4 | 8 | 7 | 16 | |
Interest | 29 | 44 | 66 | 73 | 53 |
Depreciation | 74 | 86 | 109 | 124 | 133 |
Profit before tax | 161 | 383 | 522 | 291 | 541 |
Tax % | 37% | 34% | 32% | 33% | 34% |
101 | 253 | 353 | 196 | 358 | |
EPS in Rs | 24.48 | 60.84 | 85.03 | 47.14 | 82.91 |
Dividend Payout % | 0% | 0% | 6% | 11% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 18% |
TTM: | 32% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
TTM: | 83% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 11% |
1 Year: | 45% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 25% |
Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 42 | 42 | 42 | 42 | 43 |
Reserves | 432 | 684 | 1,028 | 1,213 | 1,861 |
753 | 993 | 879 | 964 | 593 | |
222 | 405 | 484 | 576 | 655 | |
Total Liabilities | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 |
1,102 | 1,068 | 1,804 | 1,767 | 2,238 | |
CWIP | 126 | 589 | 158 | 483 | 64 |
Investments | 0 | 0 | 21 | 21 | 98 |
221 | 467 | 450 | 524 | 752 | |
Total Assets | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
229 | 284 | 626 | 398 | 441 | |
-197 | -455 | -437 | -401 | -262 | |
-32 | 195 | -200 | -8 | -164 | |
Net Cash Flow | 1 | 24 | -11 | -11 | 15 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 52 | 60 | 28 | 34 | 33 |
Inventory Days | 51 | 74 | 69 | 90 | 105 |
Days Payable | 69 | 42 | 36 | 57 | 50 |
Cash Conversion Cycle | 34 | 92 | 61 | 67 | 88 |
Working Capital Days | -4 | 26 | 15 | 25 | 57 |
ROCE % | 29% | 32% | 17% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Management of the Company is participating in the 4th MACM Invest India Global Conference on 22.05.2025.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 16 May
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
8 May - Epigral Limited submits transcript of conference call held on 05.05.2025 discussing Q4 & FY 2025 - results.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 May - Newspaper Publication - Audited Financial Results - 31.03.2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
5 May - Audio recording of Epigral's Q4 & FY25 results conference call released on 5 May 2025.
Annual reports
Concalls
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Apr 2024Transcript PPT
-
Apr 2024Transcript PPT REC
-
Apr 2024TranscriptNotesPPT
-
Jan 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Apr 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Apr 2022Transcript PPT
-
Apr 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]